India’s pharmaceutical industry is quietly proving its strength on the global stage. Even in a year marked by pricing pressure, regulatory hurdles, and geopolitical uncertainty, exports crossed an impressive ₹2.86 lakh crore in FY26. This resilience comes from India’s role as a trusted supplier of affordable medicines, along with growing demand for generics, vaccines, and specialty drugs.
With companies expanding into complex therapies and benefiting from government support like the PLI scheme, the sector is evolving fast. For investors, this makes pharma stocks particularly interesting right now. As we step into May 2026, here’s a look at some of the best pharma stocks to watch.
| Rank | Company | Market Cap (₹ Cr) | 5Y Avg Cash Flow Margin (%) | Debt to Equity |
| 1 | Sun Pharma | ₹4,37,518.70 | 20.35% | 0.03 |
| 2 | Torrent Pharma | ₹1,43,900.20 | 24.51% | 0.42 |
| 3 | Lupin Ltd | ₹1,07,382.20 | 11.32% | 0.32 |
| 4 | Dr. Reddy's Laboratories | ₹1,07,184.00 | 16.69% | 0.14 |
| 5 | Mankind Pharma Ltd | ₹93,208.38 | 17.80% | 0.58 |
| 6 | Aurobindo Pharma | ₹79,918.30 | 12.52% | 0.25 |
| 7 | Glenmark Pharma | ₹67,550.41 | 3.13% | 0.28 |
| 8 | Laurus Labs Ltd | ₹62,968.87 | 14.76% | 0.60 |
| 9 | IPCA Laboratories Ltd | ₹38,816.75 | 14.73% | 0.16 |
Note: The rank has been assigned based on market capitalisation of these stocks.
Sun Pharma is currently in focus due to its US$11.75 billion acquisition of Organon, one of the largest outbound deals by an Indian pharma company. The deal is expected to significantly expand its global presence, especially in women’s health, biosimilars, and specialty drugs.
The company is also exploring multiple funding options, including raising nearly $10 billion through bonds and internal accruals, to finance the acquisition.
Lupin is seeing steady activity across approvals and expansion. It received US FDA approval for Glycerol Phenylbutyrate and launched Dapagliflozin and Metformin ER in the US market. The VISUfarma acquisition is expected to further strengthen its ophthalmology portfolio. However, ANVISA rejection in Brazil remains a setback. With an EPS of ₹25.74, ROCE at 21.53%, and PE of 32.72, performance remains stable.
Glenmark is focusing on innovation-led growth and global expansion. It has received US FDA approval for Progesterone Vaginal Inserts and has begun direct commercialisation of RYALTRIS in the US. It has also launched GLIPIQ in India to expand in treatments for diabetes. With EPS of ₹14.29 and a ROCE of 16.02%, it has further plans of introducing new medicines in the market.
Laurus Labs has reported a strong FY26 performance with revenue rising 23% to ₹6,813 crore and PAT increasing 148%, driven by CDMO growth. EBITDA margin has expanded to 26.8%. The company raises its CapEx plan to ₹3,000 crore for expansion. With EPS at 5.17, ROCE at 23.34%, and PE of 70.85, growth remains strong with premium valuations.
| Rank | Company | 1Y Return (%) | 6M Return (%) | 5Y CAGR (%) |
| 1 | Laurus Labs Ltd | 88.43% | 18.81% | 18.82% |
| 2 | Glenmark Pharmaceuticals Ltd | 71.92% | 33.56% | 33.37% |
| 4 | Granules India Ltd | 54.15% | 28.89% | 15.09% |
| 6 | J B Chemicals & Pharma Ltd | 33.41% | 23.81% | 24.26% |
| 7 | Natco Pharma Ltd | 31.43% | 40.54% | 3.82% |
| 8 | Torrent Pharmaceuticals Ltd | 30.13% | 20.31% | 26.65% |
| 9 | Wockhardt Ltd | 18.71% | 13.57% | 25.56% |
Note: The rank has been assigned based on 1-year returns given by these stocks.
India’s pharmaceutical sector continues to stand out as a resilient and structurally strong space within the broader market. Backed by steady export growth, increasing global demand for generics, and a clear shift towards specialty drugs and complex therapies, the industry offers a balanced mix of stability and growth.
For investors, pharma remains a compelling sector in May 2026, but stock selection is key. Factors such as regulatory approvals, product pipeline, margins, and global expansion strategies should be closely tracked before making investment decisions.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: May 5, 2026, 5:44 PM IST
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
